UNI-MB - logo
UMNIK - logo
 
E-viri
Celotno besedilo
Recenzirano
  • Atypical Antipsychotics
    Chouinard, Guy; Chouinard, Virginie-Anne

    Psychotherapy and psychosomatics, 01/2008, Letnik: 77, Številka: 2
    Journal Article

    Chronic illness can result in chronicity of clinical practice. As we have moved away from prescribing classical antipsychotics and tricyclic antidepressants, issues remain with the use of atypical antipsychotics and second-generation antidepressants that need to be addressed, namely, iatrogenic discontinuation syndromes and supersensitivity psychiatric symptoms. An optimal maintenance drug treatment consists of regular attempts to reduce the dose by finding a minimal therapeutic dose, regularly asking the question of when to reduce or withdraw treatment and for which patients, and moreover, why it is difficult to decrease a given drug treatment. Recently, Falloon 1 proposed that maintenance pharmacotherapy in schizophrenia will depend on finally finding minimally effective doses through 'extensive training in stress management'. In the long-term treatment of major depression, Fava 2 has hypothesized that antidepressants can aggravate the course of depressive illness. Lambert 3 recently suggested that 'antipsychotic-switching syndromes', which include discontinuation syndromes, are a 'major barrier' to adjusting antipsychotic treatment. In this paper, we propose that to achieve optimal maintenance treatment with antipsychotics, and to reduce or withdraw antipsychotics effectively, we must distinguish syndromes associated with discontinuing antipsychotics, such as supersensitivity psychosis, from true relapse. While the prevalence and incidence of drug-induced movement disorder(s) (DIMD) has continuously decreased with atypical antipsychotics, DIMD persist as do psychiatric and psychiatric-like symptoms associated with DIMD, and these must also be identified and evaluated. Persistent DIMD have been found to be a predictor of the later emergence of tardive dyskinesia (TD) and supersensitivity psychosis 4. At present, we need to determine the relative risk of iatrogenic discontinuation syndromes, DIMD and DIMD psychiatric symptoms resulting from atypical antipsychotics. Copyright © 2006 S. Karger AG, Basel PUBLICATION ABSTRACT